Table 1.
Baseline demographics
|
N = 200 n, % |
|
|---|---|
| Demographics | |
| Age (mean ± SD) | 41.1 ± 15.5 |
| Female (%) | 99 (49.5) |
| Caucasian (%) | 192 (96) |
| Ulcerative colitis (%) | 70 (35) |
| Crohn’s disease (%) | 129 (64.5) |
| Indeterminate colitis (%) | 1 (0.5) |
| Previous resection surgery (%) | 56 (28) |
| IBD therapy | |
| Aminosalycilate monotherapy (%) | 32 (16) |
| Immunomodulator (%) | 11 (5.5) |
| Anti-TNF monotherapy (%) | 58 (29) |
| Anti-TNF + immunomodulator (combination) (%) | 32 (16) |
| Vedolizumab (%) | 21 (10.5) |
| Vedolizumab + immunomodulator (%) | 6 (3) |
| Ustekinumab (%) | 5 (2.5) |
| Ustekinumab + immunomodulator (%) | 5 (2.5) |
| Tofacitinib (%) | 7 (3.5) |
| Budesonide (%) | 15 (7.5) |
| Prednisone (%) | 28 (14) |
| No maintenance therapy (%) | 14 (7) |
| Any immunosuppressant (%) | 154 (77) |
| GI clinic appointments in past year (median, range) | 2 (1–14) |
| University of Wisconsin PCP (%) | 100 (50) |
| Active online communication portal (%) | 171 (85.5) |
SD standard deviation; 5-ASA 5-aminosalicylate; TNF tumor necrosis factor; PCP primary care provider